Ep. 1: Updated HERIZON-GEA-01 Trial Results Show Survival Benefit With Zanidatamab-Based Regimens at ESMO 2026
Key Points
- An updated analysis from the phase 3 HERIZON-GEA-01 trial showed a statistically significant overall survival (OS) benefit with zanidatamab plus chemotherapy compared with trastuzumab plus chemotherapy in HER2-positive advanced or metastatic gastroesophageal adenocarcinoma.
- Median OS was 22.9 months with zanidatamab plus chemotherapy versus 19.6 months with trastuzumab plus chemotherapy.
- Adding tislelizumab to zanidatamab plus chemotherapy resulted in a median OS of 27 months.
Updated findings from the phase 3 HERIZON-GEA-01 trial presented at the 2026 European Society for Medical Oncology (ESMO) Congress provide further evidence supporting zanidatamab-based regimens as a first-line treatment option for patients with HER2-positive advanced or metastatic gastroesophageal adenocarcinoma.
In a discussion about the trial, Samuel J. Klempner, MD, of Massachusetts General Hospital, and Shruti Patel, MD, of Stanford Medicine, shared the latest research and its clinical implications.
With an additional 9.4 months of follow-up, the analysis demonstrated a statistically significant OS benefit with zanidatamab plus chemotherapy compared with trastuzumab plus chemotherapy, establishing a clinically meaningful advantage over the HER2-directed backbone, Dr. Patel said.
Median OS was 22.9 months with zanidatamab plus chemotherapy versus 19.6 months with trastuzumab plus chemotherapy (HR, 0.76; 95% CI, 0.62-0.93; P = .0088). These findings reinforce zanidatamab’s potential to improve outcomes in a patient population with historically poor survival, according to Dr. Klempner.
Furthermore, the addition of tislelizumab to zanidatamab plus chemotherapy showed encouraging long-term outcomes. Median OS with the triplet reached 27 months compared with 22.9 months with zanidatamab plus chemotherapy alone.
The triplet regimen also demonstrated a 36-month OS rate of 39.8% compared with 31.5% with zanidatamab plus chemotherapy and 22.9% with trastuzumab plus chemotherapy.
“A 40% 3-year landmark survival rate is impressive and an improvement upon what we saw with the [zanidatamab] doublet,” Dr. Klempner said.